NephroGenex prices IPO at $12, the low end of the range
NephroGenex, a clinical-stage biotech developing treatments for diabetic nephropathy, raised $37 million by offering 3.1 million shares at $12, the low end of the range of $12 to $14. NephroGenex plans to list on the NASDAQ under the symbol NRX. NephroGenex initially filed confidentially on November 8, 2013. Aegis Capital Corp. acted as the sole bookrunner on the deal.